Related Experiment Video

Updated: Apr 13, 2026

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

8.2K

A coronary artery disease-associated SNP rs6903956 contributed to asymptomatic hyperuricemia susceptibility in Han

Jianfen Meng1,2, Wenfeng Tan3, Yujing Zhu4

  • 1Department of Rheumatology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China. jianfenmeng@163.com.

Lipids in Health and Disease
|May 1, 2015
PubMed

Insights

A specific gene variant (rs6903956) linked to coronary artery disease risk is associated with asymptomatic hyperuricemia in Han Chinese individuals. This finding suggests a genetic connection between hyperuricemia and cardiovascular disease.

Area of Science:

  • Genetics
  • Cardiovascular Disease Research
  • Metabolic Disorders

Background:

  • Coronary artery disease (CAD) is a significant health concern.
  • Asymptomatic hyperuricemia (aHU) is a condition characterized by elevated uric acid levels without symptoms.
  • Investigating genetic predispositions for aHU is crucial for understanding its link to cardiovascular health.

Purpose of the Study:

  • To determine the association between the CAD risk single nucleotide polymorphism (SNP) rs6903956 and the susceptibility to asymptomatic hyperuricemia (aHU).
  • To explore the potential of rs6903956 as an independent risk factor for aHU in the Han Chinese population.

Main Methods:

  • A case-control study involving 221 aHU patients and 447 healthy controls.
  • Genotyping of the SNP rs6903956 was performed using TaqMan probe technology.
  • Multivariate logistic regression analysis was employed to assess risk factors, adjusting for established CAD risk factors.

Main Results:

  • Significant differences in genotype and allele frequencies of rs6903956 were observed between aHU cases and controls (p<0.001).
  • The AA genotype of rs6903956 was strongly associated with aHU (OR=8.672, p<0.001).
  • rs6903956 was identified as an independent risk factor for aHU susceptibility, even after adjusting for other cardiovascular risk factors.

Conclusions:

  • This study provides the first evidence of a genetic link between the CAD-associated SNP rs6903956 and aHU in the Han Chinese population.
  • The findings support a close relationship between hyperuricemia and coronary artery disease through shared genetic factors.
  • rs6903956 may serve as a potential genetic marker for aHU risk.
Abstract

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.4K

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
20.1K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.8K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
126
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
92
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
150